| Document Date: 2014-09-30 15:05:30
Open Document File Size: 212,95 KBShare Result on Facebook
City Wilmington / / Company AstraZeneca Pharmaceuticals LP. / Ames / AstraZeneca Group / / Event Product Recall / Product Issues / FDA Phase / / Facility I store MOVANTIK / Store MOVANTIK / / IndustryTerm healthcare / chemical / / MedicalCondition neoplasms / cancer of the stomach / chronic non-cancer pain / headache / arthritis / nausea / hyperhidrosis / severe hypersensitivity / peritoneal metastases / stomach ulcer / diarrhea / end-stage renal disease / constipation / peptic ulcer disease / Back pain / diverticular disease / opioid withdrawal symptoms / intestinal obstruction / tumor / abdominal pain / Ogilvie’s syndrome / adenomas / cancer / tumors / disease / chills / Carcinogenesis / chronic / ESRD / Crohn’s disease / pain / vomiting / blister / opioid-induced constipation / renal failure / withdrawal symptoms / joint pain / / MedicalTreatment enema / hemodialysis / Dialysis / / Organization U.S. Food and Drug Administration / DOSAGE AND ADMINISTRATION / FDA / / / Position investigator / pharmacist / Major / / Product efavirenz / itraconazole / symptoms / Swallow tablets / carbamazepine / polyethylene glycol / clarithromycin / erythromycin / cimetidine / mannitol / rifampin / naloxone / Opioid / MOVANTIK / ketoconazole / 5.2 Opioid / / ProvinceOrState Rhode Island / / Technology Pharmacokinetics / Pharmacodynamics / dialysis / / URL www.fda.gov/medwatch / www.MOVANTIK.com / /
SocialTag |
[removed]HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use MOVANTIK safely and effectively. See full prescribing information for MOVANTIK. MOVANTIK™ (naloxegol) tabl